Was the Marex Group (MRX) CEO’s share sale under a Rule 10b5-1 plan?

Yes. The filing states the sale was effected under a Rule 10b5-1 trading plan entered into on March 12, 2026. Such plans pre-schedule trades, indicating these transactions were planned in advance rather than timed discretionarily.

Marex CEO sells 37,143 shares in planned trade

Marex Group plc Chief Executive Officer Ian T. Lowitt reported open-market sales of a total of 37,143 Ordinary Shares on June 12, 2026, executed under a pre-arranged Rule 10b5-1 plan.

Filing Impact

(Very High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Marex Group plc Chief Executive Officer Ian T. Lowitt reported open-market sales of a total of 37,143 Ordinary Shares on June 12, 2026, executed under a pre-arranged Rule 10b5-1 plan. The shares were sold at weighted average prices in the low-$60s per share.

Following these transactions, Lowitt directly holds 2,831,358 Ordinary Shares, which includes 194,411 shares underlying deferred bonus plan awards that represent contingent rights to receive one share each upon vesting and settlement.

Insider Trade Summary 10b5-1

Net Seller: 37,143 shares

Net Sell 2 txns

Insider Lowitt Ian T

Role Chief Executive Officer

Sold 37,143 shs ($2.32M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	32,813	$62.2916	$2.04M
Sale	Ordinary Shares	4,330	$62.9384	$273K

Holdings After Transaction: Ordinary Shares — 2,831,358 shares (Direct)

Footnotes (4)

F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on March 12, 2026.
F2. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $61.81 to $62.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $62.81 to $63.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4. The number of ordinary shares reported herein includes 194,411 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

Key Figures

Shares sold (total): 37,143 shares First trade size: 4,330 shares First trade weighted average price: $62.9384 per share +4 more

7 metrics

Shares sold (total) 37,143 shares Ordinary Shares sold on June 12, 2026

First trade size 4,330 shares Open-market sale of Ordinary Shares

First trade weighted average price $62.9384 per share Prices ranged from $62.81 to $63.37

Second trade size 32,813 shares Open-market sale of Ordinary Shares

Second trade weighted average price $62.2916 per share Prices ranged from $61.81 to $62.80

Shares held after transactions 2,831,358 shares Directly held Ordinary Shares following sales

Deferred bonus plan shares 194,411 shares Underlying deferred bonus plan awards included in holdings

Key Terms

Rule 10b5-1 plan, weighted average price, deferred bonus plan awards, contingent right

4 terms

Rule 10b5-1 plan regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on March 12, 2026."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

deferred bonus plan awards financial

"The number of ordinary shares reported herein includes 194,411 shares underlying deferred bonus plan awards previously granted to the Reporting Person."

Deferred bonus plan awards are payments promised to employees or executives that are earned now but paid out later, often only if certain performance goals are met or the employee remains with the company. For investors, they matter because they influence management’s incentives and company expenses over time—like a delayed paycheck that encourages someone to stay and meet targets—and can affect future cash needs, reported compensation costs, and potential share dilution.

contingent right financial

"Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Marex Group (MRX) CEO Ian T. Lowitt report in this Form 4?

Ian T. Lowitt reported selling 37,143 Marex Group Ordinary Shares in open-market transactions. These trades occurred on June 12, 2026, and were executed pursuant to a pre-arranged Rule 10b5-1 trading plan disclosed in the filing’s footnotes.

How many Marex Group (MRX) shares did the CEO sell and at what prices?

The CEO sold 37,143 Ordinary Shares in two blocks of 4,330 and 32,813 shares. The weighted average sale prices were $62.9384 and $62.2916 per share, with individual trade prices ranging from $61.81 to $63.37.

How many Marex Group (MRX) shares does the CEO hold after these sales?

After the reported sales, Ian T. Lowitt directly holds 2,831,358 Marex Group Ordinary Shares. This total includes both currently held shares and shares underlying deferred bonus plan awards that may be delivered upon future vesting and settlement.

What is disclosed about the price ranges for the Marex Group (MRX) CEO’s sales?

The filing reports weighted average prices but notes underlying trades. One block sold between $61.81 and $62.80 per share, and the other between $62.81 and $63.37. The reporting person offers to provide full price breakdowns upon request.

What are the deferred bonus plan awards mentioned for Marex Group (MRX) CEO?

The CEO’s reported holdings include 194,411 shares underlying deferred bonus plan awards. Each award represents a contingent right to receive one Marex Group Ordinary Share upon vesting and settlement of the applicable deferred compensation award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/16/2026 - 04:05 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lowitt Ian T

(Last)

(First)

(Middle)

C/O MAREX GROUP PLC, 155 BISHOPSGATE

(Street)

LONDON

UNITED KINGDOM

EC2M 3TQ

(City)

(State)

(Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Marex Group plc [ MRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	06/12/2026		S⁽¹⁾		32,813	D	$62.2916⁽²⁾	2,835,688	D
Ordinary Shares	06/12/2026		S⁽¹⁾		4,330	D	$62.9384⁽³⁾	2,831,358⁽⁴⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on March 12, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $61.81 to $62.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $62.81 to $63.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The number of ordinary shares reported herein includes 194,411 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

	/s/ Scott Linsley as Attorney-in-Fact, for Ian T. Lowitt	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR